Financial Report: Pfizer

Pfizer               
4Q Revenues: $14.0 billion (+2%)
4Q Loss: $394 million (earnings were $12.3 billion 4Q17)
FY Revenues: $53.6 million (+2%)
FY Earnings: $11.2 billion  (-48%)
Comments: Innovative health sales were $8.9 million in the quarter, up 6% to $5.1 billion. Lyrica sales were up 8% to $1.2 billion in the quarter. Ibrance sales were $1.1 billion, up 58%. Eliquis revenues were $910 million, up 28%. Xeljanz sales were $553 million, up 35%. Prevenar 13 sales were down 1% to $1.5 billion. Enbrel sales were down 17% to $524 million due continued biosimilar competition. Essential health sales were down 4% in the quarter, with 13% operational decline in the Legacy Established Products (LEP) portfolio in developed markets, primarily driven by industry-wide pricing challenges in the U.S. and generic competition; a 14% operational decline in the Sterile Injectable Pharmaceutical (SIP) portfolio in developed markets, primarily due to increased competition across the portfolio and continued legacy Hospira product shortages in the U.S.; and a 10% operational decline in the Peri-LOE Products portfolio in developed markets, primarily due to expected declines in Lyrica in developed Europe and Pristiq.